Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Language
Publication year range
1.
Braz J Infect Dis ; 11(4): 423-5, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17873998

ABSTRACT

Chromosomally-mediated reduced susceptibility to ciprofloxacin narrows the therapeutic options in enteric fever. We made a molecular comparison of clinical isolates of fluoroquinolone-resistant strains of Salmonella enterica serotype Typhi from January 2001 to May 2003; 178 isolates were subjected to antimicrobial susceptibility testing by the Kirby-Bauer method of disk diffusion, and agar dilution was used to determine the minimum inhibitory concentration (MIC) to ciprofloxacin. Nalidixic-acid resistant strains (NARST) were observed in 51% of the isolates, of which 98.9% had decreased susceptibility (MIC> or =0.125-1 microg/mL) to ciprofloxacin. A single strain (4 microg/mL) was resistant to ciprofloxacin and double mutations were found in the gyrA gene (76 Asp->Asn, 44 leu->Ileu). Among seven NARST strains with reduced susceptibility, a single mutation was found in five strains, one of which had 76 Asp->Asn and two each had mutations at 87 Asp->Asn and 72 Phe->Tyr, respectively); no mutations could be detected in two isolates. Routine antimicrobial surveillance, coupled with molecular analysis of fluoroquinolone resistance, is crucial for revision of enteric fever therapeutics.


Subject(s)
Anti-Infective Agents/pharmacology , Ciprofloxacin/pharmacology , Mutation , Nalidixic Acid/pharmacology , Salmonella typhi/drug effects , DNA, Bacterial/genetics , Drug Resistance, Bacterial/genetics , Humans , India , Microbial Sensitivity Tests , Polymerase Chain Reaction , Salmonella typhi/genetics
2.
Braz. j. infect. dis ; Braz. j. infect. dis;11(4): 423-425, Aug. 2007. tab
Article in English | LILACS | ID: lil-460705

ABSTRACT

Chromosomally-mediated reduced susceptibility to ciprofloxacin narrows the therapeutic options in enteric fever. We made a molecular comparison of clinical isolates of fluoroquinolone-resistant strains of Salmonella enterica serotype Typhi from January 2001 to May 2003; 178 isolates were subjected to antimicrobial susceptibility testing by the Kirby-Bauer method of disk diffusion, and agar dilution was used to determine the minimum inhibitory concentration (MIC) to ciprofloxacin. Nalidixic-acid resistant strains (NARST) were observed in 51 percent of the isolates, of which 98.9 percent had decreased susceptibility (MIC>0.125-1mug/mL) to ciprofloxacin. A single strain (4 mug/mL) was resistant to ciprofloxacin and double mutations were found in the gyrA gene (76 Asp->Asn, 44 leu->Ileu). Among seven NARST strains with reduced susceptibility, a single mutation was found in five strains, one of which had 76 Asp->Asn and two each had mutations at 87 Asp->Asn and 72 Phe->Tyr, respectively); no mutations could be detected in two isolates. Routine antimicrobial surveillance, coupled with molecular analysis of fluoroquinolone resistance, is crucial for revision of enteric fever therapeutics.


Subject(s)
Humans , Anti-Infective Agents/pharmacology , Ciprofloxacin/pharmacology , Mutation , Nalidixic Acid/pharmacology , Salmonella typhi/drug effects , DNA, Bacterial/genetics , Drug Resistance, Bacterial/genetics , India , Microbial Sensitivity Tests , Polymerase Chain Reaction , Salmonella typhi/genetics
SELECTION OF CITATIONS
SEARCH DETAIL